Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone

Autor: Sonia Messina, Maria Grazia De Pasquale, Giuseppe Vita, Gian Luca Vita, Francesca Polito, Antonino Naro, Domenica Altavilla, Anna Mazzeo, Emanuele Rizzuto, Francesco Squadrito, Natasha Irrera, M'hammed Aguennouz, Antonio Musarò, Alba Migliorato, Massimo Russo, Alessandra Bitto
Jazyk: angličtina
Rok vydání: 2009
Předmět:
Male
Flavocoxid
Necrosis
Duchenne muscular dystrophy
Anti-Inflammatory Agents
Electrophoretic Mobility Shift Assay
medicine.disease_cause
Catechin
Muscular Dystrophies
Mice
muscle degeneration
mdx
nfkb
anti-inflammation
anti-oxidante
flavoxid
oxidative stress
Creatine Kinase
limbrel®
Immunohistochemistry
Drug Combinations
Neurology
Methylprednisolone
Cytokines
Tumor necrosis factor alpha
mdx mice
medicine.symptom
flavocoxid
Signal Transduction
medicine.drug
medicine.medical_specialty
nf-kappa b
duchenne muscular dystrophy
limbrel (r)
medical food
methylprednisolone
nf-κb
Developmental Neuroscience
In vivo
Internal medicine
medicine
Animals
Muscle
Skeletal

Peroxidase
Arachidonate 5-Lipoxygenase
business.industry
DNA
Hydrogen Peroxide
medicine.disease
Mice
Inbred C57BL

Endocrinology
Prostaglandin-Endoperoxide Synthases
Mice
Inbred mdx

business
Ex vivo
Oxidative stress
Popis: Muscle degeneration in dystrophic muscle is exacerbated by the endogenous inflammatory response and increased oxidative stress. A key role is played by nuclear factor(NF)-kappaB. We showed that NF-kappaB inhibition through compounds with also antioxidant properties has beneficial effects in mdx mice, the murine model of Duchenne muscular dystrophy (DMD), but these drugs are not available for clinical studies. We evaluated whether flavocoxid, a mixed flavonoid extract with anti-inflammatory, antioxidant and NF-kappaB inhibiting properties, has beneficial effects in mdx mice in comparison with methylprednisolone, the gold standard treatment for DMD patients. Five-week-old mdx mice were treated for 5 weeks with flavocoxid, methylprednisolone or vehicle. The evaluation of in vivo and ex vivo functional properties and morphological parameters was performed. Serum samples were assayed for oxidative stress markers, creatine-kinase (CK) and leukotriene B-4. Cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), tumor necrosis factor-alpha, p-38, JNK1 expression was evaluated in muscle by western blot analysis. NF-kappaB binding activity was investigated by electrophoresis mobility shift assay. The administration of flavocoxid: (1) ameliorated functional properties in vivo and ex vivo; (2) reduced CK; (3) reduced the expression of oxidative stress markers and of inflammatory mediators; (4) inhibited NF-kappaB and mitogen-activated protein kinases (MAPKs) signal pathways; (5) reduced muscle necrosis and enhanced regeneration. Our results highlight the detrimental effects of oxidative stress and NF-kappaB, MAPKs and COX/5-LOX pathways in the dystrophic process and show that flavocoxid is more effective in mdx mice than methylprednisolone.
Databáze: OpenAIRE